Rapid Therapeutic Science Laboratories (RTSL) Stock Analysis & Winston Score

Rapid Therapeutic Science Laboratories (RTSL) is a small Canadian healthcare company focused on drug delivery technology. Its main product is a proprietary inhaler device designed to deliver pharmaceutical compounds — including psychedelic-based medicines like psilocybin — quickly and precisely into the body. The company targets the emerging psychedelic-assisted therapy market, working toward clinical and commercial applications in mental health treatment.

RTSL generates little to no revenue at this stage, operating primarily as a development-stage company that spends on research, device development, and regulatory work rather than product sales. It is based in Canada and is a very small company by any measure, with a market cap near zero and negative returns on capital. The key risk is straightforward: the company must successfully navigate regulatory approval for both its devices and the controlled substances they deliver, while also raising enough capital to survive — a significant challenge for any pre-revenue medical device firm.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

YoY Growth Rate

EPS data limited

Insider Activity

58.2%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$0 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Rapid Therapeutic Science Laboratories has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-2.6%

Weak — -2.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

-89%

Weak — only -89% of profit becomes cash

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial